Assess Osteolytic Bone Lesions in Multiple Myeloma with Collagen Hybridizing Peptides (CHPs)

Multiple myeloma (MM) involves the uncontrolled proliferation of plasma cells in the bone marrow, often accompanied by bone marrow fibrosis, characterized by abnormal collagen deposition.

Collagen Hybridizing Peptides (CHPs) selectively bind and quantify denatured collagen, a powerful tool for researchers looking to:

  • Accelerate Preclinical Drug Development by improving in vivo imaging of osteolytic bone lesions in mouse models, compared to micro-CT
  • Decipher the complex role of ECM remodeling by directly visualizing protease-degraded collagen within the multiple myeloma bone marrow microenvironment.

CHPs: Illuminating Collagen's Role in Multiple Myeloma

Explore the potential of targeted collagen analysis to improve understanding and treatment of Multiple Myeloma. Download our application flyer for details on how CHPs can advance your research.

See the Data

A versatile and sensitive solution for fibrosis characterization

CHPs enable the precise measurement of inflammation and tissue damage in a number of conditions.

Intensity of BCHP staining correlates with disease activity in MASH mouse model

At 3Helix, our CHP products provide:

  • Compatibility with most dyes, imaging probes, and automated staining platforms
  • Utility in histology, in vivo studies, and 3D cell cultures
  • Flexibility for use across any animal model and in human studies
  • The only product on the market to stain damaged collagen with applications available in total collagen staining

Our CHP products are conjugated with a variety of detection motifs for brightfield and fluorescence detection, and they can be customized to meet your unique needs. Visit our products page to learn more.

Explore our Products

Want to learn how CHPs can accelerate your Multiple Myeloma research or clinical trial?

Our experts are here to help.

Contact Us